# Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

> **NCT03588936** · PHASE1 · TERMINATED · sponsor: **Medical College of Wisconsin** · enrollment: 2 (actual)

## Conditions studied

- Acute Leukemia
- Chronic Leukemia
- Lymphoma
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Nivolumab (.25 mg/kg)
- **DRUG:** Tocilizumab
- **DRUG:** Nivolumab (.5 mg/kg)

## Key facts

- **NCT ID:** NCT03588936
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-14
- **Primary completion:** 2020-07-15
- **Final completion:** 2020-07-15
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Poor accrual and loss of funding.
- **Last updated:** 2021-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03588936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03588936, "Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03588936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*